GlassScriptPhysician profile
Ira S Solomon
NPI 1790757151
$2,969.43
in general payments reported to CMS, 2019-2025
21 companies · $406 in 2025
The $406 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $749 · 2020: $120 · 2021: $295 · 2022: $549 · 2023: $347 · 2024: $504 · 2025: $406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,257.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,257.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $415.66 | 2019-2023 | |
| Aerie Pharmaceuticals, INC. | $358.64 | 2019-2021 | |
| Rxsight INC | $318.69 | 2022-2024 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Sight Sciences, INC. | $271.15 | 2022 | |
| Sun Pharmaceutical Industries INC. | $253.65 | 2019-2025 | Cequa |
| Astellas Pharma US INC | $248.02 | 2024 | Izervay |
| Abbvie INC. | $230.68 | 2022-2025 | Durysta, Vuity, Alphagan P |
| Alcon Vision LLC | $173.85 | 2022-2025 | Rocklatan |
| Bausch & Lomb Americas INC. | $128.93 | 2022-2025 | Vyzulta, Prolensa, Miebo |
| Regeneron Healthcare Solutions, INC. | $121.64 | 2019 | |
| Allergan, INC. | $114.46 | 2019-2022 | |
| Glaukos Corporation | $107.94 | 2025 | |
| Harrow Eye, LLC | $46.20 | 2024-2025 | Vevye |
| Ani Pharmaceuticals, INC. | $29.22 | 2025 | Iluvien |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $27.98 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $27.76 | 2023 | Acthar |
| Dompe US, INC. | $27.10 | 2021 | |
| Kala Pharmaceuticals, INC. | $23.51 | 2022 | |
| Ocular Therapeutix, INC. | $17.95 | 2023 | Dextenza |
| Amgen INC. | $14.71 | 2024 | Tepezza |
| Biotissue Holdings INC. | $11.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ira Solomon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.